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Abstract
The obligate intracellular parasite Toxoplasma gondii secretes effector proteins into the host cell that manipulate the
immune response allowing it to establish a chronic infection. Crosses between the types I, II and III strains, which are
prevalent in North America and Europe, have identified several secreted effectors that determine strain differences in mouse
virulence. The polymorphic rhoptry protein kinase ROP18 was recently shown to determine the difference in virulence
between type I and III strains by phosphorylating and inactivating the interferon-c (IFNc)-induced immunity-related GTPases
(IRGs) that promote killing by disrupting the parasitophorous vacuole membrane (PVM) in murine cells. The polymorphic
pseudokinase ROP5 determines strain differences in virulence through an unknown mechanism. Here we report that ROP18
can only inhibit accumulation of the IRGs on the PVM of strains that also express virulent ROP5 alleles. In contrast, specific
ROP5 alleles can reduce IRG coating even in the absence of ROP18 expression and can directly interact with one or more
IRGs. We further show that the allelic combination of ROP18 and ROP5 also determines IRG evasion and virulence of strains
belonging to other lineages besides types I, II and III. However, neither ROP18 nor ROP5 markedly affect survival in IFNc-
activated human cells, which lack the multitude of IRGs present in murine cells. These findings suggest that ROP18 and
ROP5 have specifically evolved to block the IRGs and are unlikely to have effects in species that do not have the IRG system,
such as humans.
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Introduction
Toxoplasma gondii is a widespread intracellular parasite capable of
infecting most warm-blooded animals and is an important
opportunistic pathogen for immunocompromised individuals and
unborn fetuses. Toxoplasma resides within a non-fusogenic para-
sitophorous vacuole and has three apical secretory organelles, the
micronemes, rhoptries and dense granules, which secrete proteins
into the host cell during invasion that mediate important host-
pathogen interactions [1]. In general, an asymptomatic but
chronic infection is established in immunocompetent humans.
However, in rare cases Toxoplasma can cause severe disease even in
immunocompetent people. Diverse disease outcomes may be due
to genetic differences between infecting strains [2].
Toxoplasma has a partially clonal population structure of 12–15
[3,4] haplogroups with the majority of North American and
European isolates belonging to the canonical types I, II and III
strains [5,6], although haplogroup 12 has been recently shown to
be prevalent in wild animals in North America [6]. In mice, these
strains differ in virulence, with type I strains having an LD100 of
just one parasite, compared to the LD50 of,103 or,105 parasites
for types II and III strains, respectively [7,8]. Type I strains may
also be more virulent in humans, as they are more frequently
isolated from cases of congenital or severe ocular toxoplasmosis
than from animals [5,9]. Interestingly, in South America, more
genetically diverse strains are isolated, while the canonical strains
are rarely found [10]. Some of these strains are associated with
high mortality rates in mice [11]. Additionally, there are high rates
of ocular toxoplasmosis in humans in South America [12,13], and
some strains isolated from French Guiana have been reported to
cause severe disseminated toxoplasmosis even in healthy individ-
uals [14]. The determinants of canonical strain-specific differences
in murine virulence are well studied, but the same determinants
for non-canonical strains or for human infection remain unknown.
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Mice and humans use divergent immune mechanisms to resist
Toxoplasma. Interferon-c (IFNc) is essential to murine Toxoplasma
resistance, and IFNc-deficient mice die after infection even with
avirulent strains [15]. Some of the important downstream effectors
of this immune activation are the IFNc-inducible immunity-
related GTPases (IRGs), which belong to the dynamin family of
GTPases and can cooperatively oligomerize to vesiculate mem-
branes. Mice deficient in individual members of the IRG family
die of toxoplasmosis, but at different stages of infection, and
expression of the IRGs is required even in non-hematopoietic cells,
suggesting IRGs have non-redundant, crucial roles in the innate
immune response against Toxoplasma [16–18]. Different IRGs are
sequentially and cooperatively loaded onto the parasitophorous
vacuole membrane (PVM) with Irgb6 and Irgb10 initiating and
stabilizing the loading of the other members [19]. The IRGs are
able to disrupt the PVM and kill the parasite [20,21].
While mice have 23 IRG genes, humans have only two IRG
genes: IRGC which is expressed only in the testis and IRGM which
is expressed independently of IFNc induction and has a truncation
in the nucleotide-binding G-domain [22]. Despite these differenc-
es, IRGM plays a role in autophagy-mediated destruction of
Mycobacterium tuberculosis and Salmonella typhimurium in human cells,
and some variants are associated with increased risk for Crohn’s
disease [23,24]. Thus, IRGM may have an immune role, but its
lack of GTPase activity suggests a distinct mechanism of action in
humans. Humans do have other known IFNc-mediated mecha-
nisms of resistance to Toxoplasma. For instance, IFNc-induced
indoleamine 2,3-dioxygenase (IDO1) degrades cellular tryptophan
for which Toxoplasma is auxotrophic, thereby inhibiting Toxoplasma
growth [25,26]. The NALP1 inflammasome also mediates the
innate immune response to Toxoplasma, and NALP1 was recently
identified as a susceptibility locus for human congenital toxoplas-
mosis [27].
Toxoplasma strain differences in evasion of murine immune
responses exist. For instance, type I strains are able to prevent the
accumulation of IRGs on the PVM, while types II and III strains
are susceptible to killing by the IRGs even when co-infecting the
same cell as a type I parasite [28]. Because strain-specific evasion
of the IRGs is correlated with increased virulence in the mouse, it
is likely that the genetic determinants of IRG evasion will also be
associated with virulence. Quantitative Trait Locus (QTL)
mapping analyses of the virulence of F1 progeny derived from
type I6II, I6III and II6III crosses have identified the genetic loci
associated with virulence, and subsequent experiments have
identified the causative genes within these loci.
ROP18, a highly polymorphic rhoptry protein kinase, was
identified as a virulence locus in the II6III QTL study and the
only virulence locus in the I6III cross [7,29]. ROP18 is highly
expressed in types I and II strains but an insertion in the promoter
prevents expression in type III strains. Addition of a type I or II
copy of ROP18 into an avirulent type III strain makes that strain
become virulent [7,11]. Recently, it was shown that type I ROP18
can phosphorylate a conserved threonine in the G-domain of
Irga6 and Irgb6, disrupting their accumulation on the PVM
[30,31]. However, type II strains have the highest percentage of
vacuoles coated with IRGs [19,28] despite the fact that a type II
copy of ROP18 is also able to make a type III strain virulent,
suggesting that other polymorphic proteins are involved in IRG
evasion [7]. ROP18 was also shown to promote the degradation of
the endoplasmic reticulum-associated transcription factor ATF6-b,
compromising CD8 T cell-mediated adaptive immune responses
[32]. Importantly, ROP18-mediated ATF6-b degradation occurs
in human as well as murine cells.
The ROP5 locus, which consists of a family of 4–10 tandem
duplicates of highly polymorphic genes encoding for rhoptry
pseudokinases that localize to the PVM, is another important
virulence determinant in mice [33,34]. Deletion of ROP5 in a type
I strain significantly attenuates virulence. Furthermore, ROP5 was
the only significant virulence locus identified in the recent I6II
QTL analysis and was the main virulence locus in the II6III QTL
study [7,34]. Both types I and III strains have a virulent ROP5
locus, but the mechanism by which ROP5 affects virulence and
which of the three major ROP5 isoforms, A, B or C, [33] are
necessary to complement the virulence of type II are not known.
A third virulence locus, identified in the II6III QTL study,
contains the rhoptry protein kinase ROP16, which in types I and
III strains leads to sustained phosphorylation and activation of
STAT3/6 [35]. It was recently shown that ROP16 and the dense
granule protein GRA15, suggested to be the fourth virulence locus
in the II6III QTL study [36], affect the accumulation of p65
guanylate binding proteins (GBPs) on the PVM in infected murine
cells [37]. Because GBPs are also dynamin family members and
were found on the same vacuoles as the IRGs, ROP16 and
GRA15 might also affect the accumulation of the IRGs on the
PVM. Furthermore, since the GBPs are present in humans,
ROP16 and GRA15 could possibly affect survival in IFNc-
stimulated human cells.
Because the murine and human immune responses to Toxoplas-
ma are so different, it cannot be assumed that ROP18, ROP5,
ROP16 and GRA15, which determine Toxoplasma virulence in
mice, similarly affect survival in human cells. Furthermore, it is
currently unknown for most of these proteins what effects they
have outside the clonal lineages from which they were identified.
Many of the exotic strains are highly virulent in mice, but because
they are so divergent from the canonical strains and the exotic
strains have not been used in QTL or gene manipulation studies, it
is not known what factors drive virulence in these strains. For
example, IRG evasion has not been measured for the exotic
strains, and it may be that this is strictly a type I phenotype.
Author Summary
Toxoplasma gondii can infect any warm-blooded animal
and is transmitted orally by consumption of tissue cysts. To
facilitate transmission, the parasite must balance induction
and evasion of host immune responses to allow parasite
growth and persistence, while avoiding excessive parasite
burden, which can kill the host before infectious cysts are
formed. Different strains of Toxoplasma have likely evolved
specific effector molecules to modulate the immune
responses of different hosts. In many mammals, including
mice but not humans, the cytokine interferon gamma
(IFNc) induces the immunity-related GTPases (IRGs), which
are essential to the murine immune response to Toxoplas-
ma. They function by binding to and disrupting the
parasite-containing vacuole. However, some Toxoplasma
strains prevent the IRGs from disrupting the parasitophor-
ous vacuole. It was previously shown that the secreted
Toxoplasma kinase ROP18 promotes virulence in mice by
phosphorylating the IRGs, leading to their inactivation. We
report that ROP18 requires another virulence factor, the
secreted pseudokinase ROP5, to prevent IRG accumulation,
and these two proteins determine the majority of strain
differences in IRG evasion, even for divergent strains for
which virulence determinants have not been studied.
Additionally, we show that ROP18 and ROP5 do not affect
Toxoplasma survival in IFNc-stimulated human cells. Thus,
ROP18 and ROP5 are strain- and host-specific determinants
of Toxoplasma immune evasion.
Toxoplasma Host and Strain Specific Immune Evasion
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In this study, we find that ROP18 can only inhibit accumulation
of the IRGs on the PVM of strains that also express virulent ROP5
alleles. Expression of ROP18 in strains that do not express virulent
ROP5 alleles does not affect IRG accumulation or in vivo virulence.
In contrast, specific ROP5 alleles can reduce IRG coating even in
the absence of ROP18 expression and directly interact with Irga6
to inhibit its oligomerization. Non-canonical strains exhibit
differences in evasion of IRG-mediated killing as well, and the
allelic combination of ROP18 and ROP5 also correlates with strain
differences in IRG evasion and virulence for these strains.
However, neither ROP18 nor ROP5 markedly affect parasite
survival in IFNc-activated human cells.
Results
Both ROP18II and ROP18I reduce IRG-mediated killing of
type III parasites
Type II strains have the highest percentage of IRG-coated
vacuoles compared to types I and III strains [19,28] even though
they possess a ROP18 allele capable of conferring virulence to a
type III strain [7]. To determine if, like ROP18I [30,31], the
increased virulence due to ROP18II is correlated with reduced
IRG coating in a type III background, we measured the
percentage of vacuoles coated with Irgb6 by immunofluorescence
in IFNc-stimulated mouse embryonic fibroblasts (MEFs) infected
with type I, II, III, III + ROP18I, or III + ROP18II (Figure 1A).
Indeed, transgenic expression in the type III strain CEP of either
ROP18I or ROP18II decreased the average number of vacuoles
coated with Irgb6 from 45% to 23% (P= 0.001) for ROP18I or
29% (P= 0.003) for ROP18II (Figure 1B). Although it is generally
assumed that once the PVM is coated, it will eventually lead to
killing of the parasite inside, it has also been shown that Toxoplasma
can escape a coated vacuole and invade a new cell [37,38].
Therefore, to measure killing of Toxoplasma, 100 parasites were
seeded on a monolayer of MEFs, either previously stimulated for
24 hours with IFNc or left untreated, and the number of plaques
that form after 4–7 days of growth was determined. Type III had
an average of 45% plaque loss when comparing plaques formed
on IFNc-stimulated MEFs to unstimulated MEFs. This percentage
plaque loss was similar to the percentage of vacuoles coated with
Irgb6, suggesting that coated vacuoles are eventually destroyed.
Furthermore, plaque loss is drastically reduced in Atg7 deficient
MEFs (Figure S1) in which the IRGs are misregulated as
previously reported for Atg5 deficient MEFs [19,39], suggesting
the killing observed is indeed due to the IRGs. Similar to the
decrease in Irgb6 coating, the plaque loss of type III + ROP18I or
ROP18II was significantly decreased to 18% (P= 0.0002) and 21%
(P= 0.0004), respectively (Figure 1B). The 23% PVM coating and
18% killing of type III + ROP18I is similar to the 25% coating and
35% plaque loss of the type I strain GT1. Thus, ROP18
expression can likely explain most of the difference in IRG
coating and killing between type I and type III strains. Despite the
ability of ROP18II to reduce IRG coating of type III strain
vacuoles and subsequent killing of the parasite, type II strains are
still very susceptible to the IRGs, with 70% Irgb6 coating and 73%
plaque loss for Pru (type II) (Figure 1B). Thus, there must be at
least one other gene involved in IRG evasion that is shared
between types I and III but different in type II.
ROP5 reduces IRG-mediated killing
It was recently demonstrated that the ROP5 cluster of
pseudokinases accounts for most of the variation in virulence
between types I and II strains and between types II and III strains,
with types I and III strains possessing a virulent ROP5 locus
[33,34]. Therefore, the ROP5 locus is an excellent candidate for
explaining strain differences in IRG evasion. We tested a potential
role of ROP5 in mediating ROP18-independent strain differences
in IRG evasion by using the S22 strain, an avirulent F1 progeny
Figure 1. A type III strain expressing type I or type II ROP18 inhibits Irgb6 accumulation and killing. WT MEFs were stimulated for
24 hours with IFNc and infected with type I (GT1), type II (Pru), type III (CEP), CEP + ROP18I or CEP + ROP18II expressing GFP. (A) Cells were fixed after
1 hour and stained by immunofluorescence for Irgb6 (Red) and with Hoechst (blue). Scale bar represents 5 mm. (B) Quantification of Irgb6 localization
on the parasite containing vacuole and percentage plaque loss after 4–7 days on stimulated MEFs compared to unstimulated MEFs. Mean + SEM,
n = 5 experiments, ***p,0.001, Student’s t test.
doi:10.1371/journal.ppat.1002784.g001
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from a II6III cross [40] which possesses the avirulent ROP18III
and ROP5II alleles. We compared the percentage plaque loss and
percentage of Irgb6 coated vacuoles between S22 and an S22
transgenic strain carrying the cosmid LC37, which contains the
ROP5 locus from the RH (type I) genome and was previously
shown to have significantly increased virulence [33]. Expression of
ROP5I significantly reduced the Irgb6 coating from 48% to 28%
(P,0.001), and the plaque loss from 38% to 27% (n.s.) (Figure 2A).
Thus, ROP5I can function independently of ROP18I/II to prevent
IRG accumulation on the PVM and subsequent killing of the
parasite.
ROP18II requires ROP5 to reduce IRG coating
While ROP5 can function independently of ROP18 in reducing
IRG accumulation on the PVM of S22 + LC37 vacuoles, type II
strains, which have a virulent allele of ROP18 and an avirulent
ROP5 locus, have a high percentage of IRG-coated vacuoles. This
suggests that either ROP18 cannot function independently of
ROP5, or that ROP18 is inhibited in the type II background. We
expressed ROP18II in S22 and in S22 + LC37 to determine if
ROP18II can function in the absence of virulent ROP5 alleles.
ROP18II only slightly reduced Irgb6 coating in S22 from 47% to
41% (n.s.) and plaque loss from 39% to 24% (n.s.). However,
ROP18II significantly reduced Irgb6 coating from 31% to 7%
(P,0.001) and plaque loss from 27% to 9% (P,0.01) when
expressed in S22 + LC37 (Figure 2A). Together, this suggests that
ROP18 needs the virulent ROP5 locus for its function. That the
Irgb6 coating and plaque loss in S22 + LC37 + ROP18II are
similar to those in RH (type I) signifies that these two genes are
sufficient to complement IRG evasion and plaque loss in the S22
background.
To determine if the interactive effect of ROP18 and ROP5 on
parasite survival also occurs in vivo, we infected outbred CD-1
mice by intraperitoneal injection with S22, S22 + ROP18II, S22
+ LC37 or S22 + LC37 + ROP18II tachyzoites expressing firefly
luciferase and followed parasite growth and dissemination using
in vivo imaging. On the third day after infection, the parasite
burden in S22 + LC37 and S22 + LC37 + ROP18II-infected
mice was 10-fold higher than in S22 or S22 + ROP18II-infected
mice. By day six, both strains containing the LC37 cosmid had
disseminated throughout the peritoneal cavity, but S22 + LC37
+ ROP18II-infected mice had 35-fold higher luciferase activity
than S22 + LC37-infected mice (P = 0.03), which in turn had 10-
fold higher activity than S22 + ROP18II-infected mice (P = 0.1)
and 30-fold higher activity than S22-infected mice (P = 0.06).
While S22 + ROP18II had a greater parasite burden than S22,
this was not significant (P = 0.27). Indeed, S22 + LC37 +
ROP18II killed 100% of the mice in the acute stage of infection
at both a low and high dose (Figure 2B and C). Likewise, in
keeping with the increased IRG evasion of S22 + LC37 but not
S22 + ROP18II, S22 + LC37 showed increased virulence
compared to S22, but S22 + ROP18II-infected mice survived the
infection and did not show significant differences compared to
S22 infected mice (Figure 2D). Thus, overall these results suggest
that ROP18 only affects virulence in the context of a virulent
ROP5 locus.
Figure 2. Virulent ROP5 promotes IRG evasion, independently of ROP18. (A) Quantification of Irgb6 localization on the parasitophorous
vacuole (PV) and percentage plaque loss on IFNc-stimulated MEFs compared to unstimulated MEFs infected with S22, S22 + ROP18II, S22 + LC37 and
S22+ LC37 + ROP18II. Mean + SEM, n.4 experiments, *p,0.05, **p,0.01, ***p,0.001, One-way ANOVA with Bonferroni correction for all pairwise
comparisons. (B) In vivo imaging of mice infected with firefly luciferase-expressing parasites of the indicated strains at days 3 and 6 post infection with
5000 parasites. One representative of 5 infected mice per strain is shown. (C) Quantification of in vivo imaging shown as average photons/sec/cm2/sr
for infected mice at days 3, 6 and 12. (D) Mouse survival of infection with indicated doses of each strain.
doi:10.1371/journal.ppat.1002784.g002
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IRG evasion differences in non-canonical strains
Although mouse virulence has been determined for many non-
canonical strains [11], it is unknown what factors determine
virulence in these strains. We wondered if virulent non-canonical
strains could also evade IRG-mediated killing, or if IRG evasion is
specific to type I strains. We measured the percentage plaque loss
in IFNc-stimulated MEFs as well as percentage Irgb6-coated
vacuoles for strains from haplogroups 1–11 [6,41]. In general,
IRG evasion correlates with virulence as strains that have a
mortality rate of greater than 90% in CD-1 mice also have 25% or
less Irgb6-coated vacuoles and plaque loss (Figure 3A). However,
some exceptions are CASTELLS and COUGAR, which exhibit
greater than 50% Irgb6 coating and plaque loss in IFNc-
stimulated MEFs, despite a high mortality rate in mice [11].
These strains may have a different mechanism underlying their
virulence in mice besides IRG evasion.
For most strains, the Irgb6 coating and plaque loss correlates
with their ROP18 allele (Figures 3A and S2) [11]. For example,
CASTELLS and P89, as well as the type III strains CEP and
VEG, have between 40% and 50% Irgb6 coating, and all of these
strains do not express ROP18 because they have a ROP18III-like
allele that contains an insertion in the promoter [11]. The strains
that express a type I-like allele of ROP18, with the exception of
BOF, display 25% or less Irgb6 coating. Type II strains and
COUGAR are highly susceptible to the IRGs with 70% and 53%
Irgb6 coating respectively, despite having the virulent ROP18II
allele. For type II strains, the avirulent ROP5 locus likely explains
the high degree of Irgb6 coating, but it is unknown what versions
of ROP5 are present in the non-canonical strains.
ROP5 sequence and expression explain strain differences
in IRG evasion
For most of the strains mentioned above, Irgb6 coating
correlates with their ROP18 allele, suggesting that they also have
a virulent ROP5 locus, as this is necessary for ROP18 to function
(Figure 2). It is currently unknown what determines the virulence
and IRG evasion properties of the ROP5I/III locus because both
copy number and amino acid sequence of the individual copies
differ between the canonical strains [33]. To identify differences
that may be associated with virulence or IRG evasion, we
sequenced the different ROP5 isoforms of strains from haplogroups
1–11 (GenBank JQ743705-JQ743783). Based on the Toxoplasma
genome sequence (www.ToxoDb.org) and our own genome
sequencing of seven non-canonical Toxoplasma strains (Minot et
al., submitted), we identified four distinct ROP5 open reading
frames that we amplified and sequenced separately using isoform
specific primers. Sequence chromatograms indicated that two or
more alleles were present for the second ROP5 reading frame. We
therefore cloned the PCR product from this ROP5 gene and
sequenced multiple clones to obtain sequences from the different
alleles, but some alleles may still be missing. Sequences from this
expanded paralog matched what has previously been called both
ROP5-B (minor) and C (major) genes (Figure 3B) [33,34]. We could
not differentiate B and C alleles for all strains if they were not
similar to the canonical strains, so we refer to them here as B
copies. We determined that besides the three major ROP5 copies
that were previously described, 2 other highly divergent ROP5
isoforms exist that we call ROP5L-A and ROP5L-B (Figures S3 and
S4). Interestingly, ROP5L-A and ROP5L-B are highly conserved
between strains, but we find that these isoforms are not expressed
in tachyzoites (Figure S3) so they will not be discussed further. The
previously described ROP5 genes (A, B and C) [33] are highly
divergent with strong evidence for diversifying selection
(Figure 3C)., especially in surface exposed residues in the kinase
domain [42]
In general, for ROP5-A and for ROP5-B and C, which cluster
together, alleles can be divided into distinct groups with the BOF,
P89, CAST and GPHT strains grouping with the virulent types I
and III alleles (Figure 3B). A second allelic group consists of the
strains VAND, RUB, GUY-KOE, GUY-DOS and GUY-MAT.
The ability to confer virulence of this allelic group is unknown but
because these strains are all highly virulent [11] and able to evade
the IRGs, these alleles are likely virulent. A third very divergent
group of alleles contains the strains MAS, CASTELLS and
TgCatBr5, but there is less diversity in the ROP5-A, B and C
isoforms present in these strains. The COUGAR allele is most
similar to but divergent from the second group, but interestingly,
COUGAR has only one B/C allele. The avirulent ROP5 locus
from type II is also divergent, and a phylogenetic analysis of all
ROP5 alleles indicates that the type II ROP5-B and C genes are
more closely related to ROP5-A than to ROP5-B or C of the other
strains. These results suggest that ROP5-B and/or C could be
important for IRG evasion and virulence since type II strains and
COUGAR have high levels of IRG coating (Figure 3A) and seem
to have either ROP5 alleles that are all ROP5-A-like (type II) or are
missing ROP5-C (COUGAR) (Figure 3B).
Next, we tested whether differences in ROP5 expression or copy
number could account for strain differences in IRG evasion. For
example, BOF has virulent ROP18 and ROP5 alleles but is highly
coated by Irgb6 (Figure 3A–B). To estimate copy number
differences between the strains we have sequenced, we plotted
the sequencing coverage of the ROP5 locus versus the average
genome coverage, as this was previously shown to be a good
estimate for copy number [43]. Most of the strains had about twice
as many reads at ROP5-A and B as the rest of the genome, while
MAS and TgCatBr5 have 3–5 copies of each gene (Figure 3D).
However, coincident with our inability to amplify ROP5-A, we
found that BOF is missing ROP5-A and has only one copy of
ROP5-B.
We also looked at ROP5 expression levels determined using
RNA-Seq data from 24 hour infections of murine bone marrow
derived macrophages with each strain (Figure 3D). BOF has barely
detectable expression of ROP5-B and no expression of ROP5-A,
likely explaining its high Irgb6 coating despite having a similar
ROP5-B/C amino acid sequence to types I and III. Indeed BOF +
LC37 has virtually no Irgb6 coating (0.33%) compared to BOF
(40% Irgb6 coating, P= 0.001) (Figure 4A). ROP5 expression levels
can also likely explain many intra-haplogroup strain differences
where ROP18 and ROP5 coding sequence are the same; for
example, VEG has higher ROP5 expression levels compared to
the other type III strain CEP, and VEG has slightly reduced IRG
coating compared to CEP. Thus, higher ROP5 expression is
correlated with reduced IRG coating, suggesting a non-enzymatic,
dose-dependent role for ROP5 in IRG evasion.
ROP5-C complements IRG evasion in type II parasites
Because the LC37 cosmid that reduced Irgb6 coating and
plaque loss in S22 and BOF contains ROP5-A, B and C it is
unknown which of these isoforms (or which combination) is
important for IRG evasion. However, the fact that type II ROP5
alleles are less divergent and more similar to ROP5-A suggests type
II is missing ROP5-B and C. Additionally, ROP5-C was previously
described as the major allele with A and B as minor alleles when
trace reads were assembled for the ROP5 coding region of types I,
II and III [34]. Therefore, we tested if ROP5-AIII, ROP5-CIII or
LC37, which contains the entire ROP5 locus, could complement
IRG evasion in the type II background. Although some of the
Toxoplasma Host and Strain Specific Immune Evasion
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effects we see in the type II background will be due to an
interaction with ROP18, because ROP18 is present in all
backgrounds, we can still compare the effects of individual ROP5
genes. We find, as expected, that expression of ROP5-AIII in the
type II strain Pru led to only a slight but significant reduction in
Irgb6 coating (51%, P,0.05), but expression of ROP5-CIII in Pru
led to a significant reduction of IRG coating (36%, P,0.001)
similar to that of Pru + LC37 (38%, P,0.001) compared to a
Figure 3. ROP5-A, ROP5-B/C and ROP18 account for strain differences in IRG evasion in non-canonical strains. (A)Quantification of
percentage of PVs with Irgb6 localization and percentage plaque loss on IFNc-stimulated MEFs compared to unstimulated MEFs infected with the
indicated strains. Strains that have greater than 90% mortality in CD-1 outbred mice [11] are indicated in red. The predicted reason for high IRG
coating is indicated below the graph, which for CEP, VEG, CASTELLS and P89 is the unexpressed ROP18III allele, and for Pru, ME49, COUGAR and BOF is
divergent or missing ROP5 alleles. (B) Phylogenetic tree of ROP5-A, B andC and previously reported major and minor alleles [34] constructed from full-
length coding nucleotide sequences using Neighbor-Joining with 1000 bootstraps. (C) Cumulative behavior, codon by codon, of synonymous (red),
nonsynonymous (green) and insertion/deletion (black) mutations in ROP5-A (left) and ROP5-B/C (right). (D) Relative expression of ROP5-A, ROP5-B/C
and ROP18 determined by RNA-Seq of murine BMDM infected for 24 hours with the indicated strains. Samples were matched for similar levels of
Toxoplasma RNA. ROP5-A and B/C copy number estimated by sequencing coverage of the ROP5 locus versus the average genome coverage for strains
for which the genome has been sequenced is indicated in the table below the graph.
doi:10.1371/journal.ppat.1002784.g003
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heterologous control (62%) (Figure 4B). The 36% IRG coated
vacuoles in Pru + ROP5-CIII is comparable to the 25% IRG
coated vacuoles for GT1, suggesting that the lack of ROP5-C may
account for the excessive IRG accumulation on type II vacuoles.
To see if ROP5-CIII can also increase the survival of type II
parasites in vivo, we infected CD-1 mice with Pru, Pru + ROP5-
AIII, Pru + ROP5-CIII or Pru + LC37. The growth and
dissemination of Pru and Pru + LC37 was determined by in vivo
imaging of luciferase activity. On the third day post infection, Pru
+ LC37-infected mice had twice the parasite burden of Pru-
infected mice (Figure 4C and D). By day six, there was 50 fold
higher luciferase activity in Pru + LC37-infected mice (P,0.0001),
and the parasites had disseminated throughout the peritoneal
cavity. Indeed, 100% of Pru + LC37-infected mice died within 11
days of infection even at the lowest dose (Figure 4E). Mice infected
with Pru parasites expressing only ROP5-AIII or ROP5-CIII
survived the infection (Figure 4E) but Pru + ROP5-CIII-infected
mice had more ruffled fur and lost significantly more weight
(Figure 4F) than Pru-infected mice throughout the course of
infection(P = 0.01 at 15 days post infection) while Pru + ROP5-
Figure 4. ROP5III-C, but not ROP5IIIA, inhibits IRG accumulation and increases mouse virulence. (A) Quantification of Irgb6 localization on
the PV in IFNc-stimulated MEFs infected with BOF and BOF + LC37. Mean + SEM, n = 3 experiments, ***p,0.001, Student’s t-test. (B) Quantification of
Irgb6 localization on the PV and percentage plaque loss on IFNc-stimulated MEFs compared to unstimulated MEFs infected with Pru, Pru + LC37, Pru
+ ROP5III-A, and Pru + ROP5III-C. Mean + SEM, n.4 experiments, *p,0.05, ***p,0.001 One-way ANOVA with Bonferroni correction for all pairwise
comparisons. (C) In vivo imaging of mice infected with firefly luciferase-expressing parasites of the indicated strains at days 3 and 6 post infection with
5000 parasites. One representative of 5 infected mice per strain is shown. (D) Quantification of in vivo imaging shown as average photons/sec/cm2/sr
for infected mice at 3 doses on days 3 and 6. (E) Mouse survival after infection with indicated strains, n.8 for each strain, combined results for doses
500, 5000 and 15000 (Pru and Pru + LC37 only). (F) Average percent change in weight over time for mice infected with the indicated strains, Mean 6
Std dev.
doi:10.1371/journal.ppat.1002784.g004
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AIII-infected mice continued to gain weight. Together, these
results suggest that while expression of ROP5-CIII can reduce Irgb6
coating of type II parasites, ROP5-CIII only partially enhances the
survival of type II parasites in vivo, and the whole ROP5 locus is
required to significantly increase virulence in mice.
ROP5 does not interact with ROP18 and is not necessary
for ROP18 kinase activity
It is not clear how ROP5 inhibits IRG accumulation at the
PVM, but other pseudokinases have been shown to serve as
protein scaffolds or to regulate the activity of kinases [44]. Since
ROP18 requires ROP5 for fully efficient IRG evasion, and there is
an interactive effect of adding ROP18 and ROP5 to the S22
strain, it is possible that ROP5 and ROP18 interact directly. To
test this hypothesis, we immunoprecipitated ROP5 and ROP18II-
HA from MEFs infected with CEP or CEP + ROP18II-HA for one
hour with or without previous IFNc stimulation. We were unable
to detect by western blot co-immunoprecipitation of ROP18 and
ROP5 (Figure 5A). Furthermore, when recombinant, tagged
ROP18 kinase domain (Lim et al., submitted) is added to cell
lysates from IFNc-stimulated or unstimulated MEFs infected for
one hour with Pru + ROP5-CIIIHA, and ROP5 is immunopre-
cipitated with anti-HA, we do not co-immunoprecipitate ROP18
(Figure S5A) indicating that there is no direct interaction between
ROP5-CIII and the ROP18 kinase domain. Next we tested the
hypothesis that ROP18 is only active in the presence of virulent
ROP5 alleles by immunoprecipitating ROP18II-HA from MEFs
infected with S22, S22 + ROP18IIHA, and S22 + LC37 +
ROP18IIHA for one hour with or without previous IFNc
stimulation for use in an in vitro kinase assay. We found that there
was no difference in the activity of ROP18 immunoprecipitated
from parasites with or without a virulent ROP5, as measured by
the phosphorylation of an optimized substrate (Lim et al.,
submitted) in vitro, (Figures 5B and S5B). This established that
ROP18 was active in all backgrounds and indicated that there are
no irreversible effects of ROP5 on ROP18 kinase activity.
ROP5 directly interacts with and inhibits the
oligomerization of Irga6
Because ROP5 does not directly interact with or irreversibly
affect ROP18 kinase activity, we next tested the hypothesis that
ROP5 directly interacts with one or more IRGs. We immuno-
precipitated HA-tagged proteins from IFNc-stimulated or un-
treated MEFs infected for one hour with Pru, Pru + ROP5-AIII-
HA, Pru + ROP5-CIII-HA, or RH + GRA15II-HA and lysed in
the presence or absence of GTPcS (a non-hydrolyzable form of
GTP). Co-immunoprecipitated proteins were separated by SDS-
PAGE and identified by mass-spectrometry. We did not recover
any ROP18 peptides, again suggesting that ROP5 does not
directly interact with ROP18. We did, however, recover 13
peptides (38% sequence coverage) from Irga6 only in the Pru +
ROP5-CIII-HA infected samples lysed in the presence of GTPcS
(Figure 5C) suggesting a specific interaction between ROP5-C and
Irga6 because the other HA-tagged, PVM associated proteins did
not co-immunoprecipitate Irga6 under these conditions. Under
different buffer conditions and in the absence of GTPcS, we also
recovered 4 peptides of Irga6 and 2 peptides (9.8% sequence
coverage) of Irgb10 only in the Pru + ROP5-CIII-HA infected
samples (data not shown). Because ROP5 lacks kinase activity [42]
but reduces IRG localization to the PVM, we wondered if Irga6
binding by ROP5 could inhibit Irga6 oligomerization, which is
necessary for its activity. To test this hypothesis, we measured the
GTP-mediated oligomerization of recombinant Irga6 by dynamic
light scattering in the presence of recombinant maltose binding
protein (MBP)-tagged ROP5 or MBP alone. We found the
predicted hydrodynamic radius of Irga6 to be reduced in the
presence of ROP5 but not MBP (Figure 5D). Thus, we find that
ROP5-CIII binds and inhibits the oligomerization of at least one
IRG.
ROP16 and GRA15 do not affect IRG evasion by
Toxoplasma
It was recently reported that p65 guanylate-binding proteins
(GBPs), members of the dynamin superfamily that includes the
IRGs, also accumulate on the Toxoplasma PVM alongside the IRGs
[37]. Because ROP16 and GRA15 were shown to affect GBP
coating, we were interested to see if ROP16 and GRA15 also
affect IRG coating. We measured the effect of ROP16 and
GRA15 on IRG coating and IRG-mediated killing in types I, II
and III genetic backgrounds. In a type I background, the deletion
of ROP16, the transgenic expression of GRA15II, or both in
combination did not significantly alter IRG coating or killing
(Figure 6A and not shown). Likewise, type IIDgra15, type II
transgenically expressing ROP16I, and type III transgenically
expressing GRA15II showed no statistical differences in Irgb6
coating or plaque loss compared to their parental strains. Thus,
while these genes may affect GBP coating, they do not significantly
alter Irgb6 accumulation.
PVM structure affects IRG accumulation
Not all of the F1 progeny in the I6II cross that have the type I
ROP5 are as virulent as type I in mice [34] indicating that there
are other genes besides ROP5 and ROP18 that affect virulence.
While the genetic location of the dense granule protein GRA2 has
not been verified as a QTL affecting virulence, an RHDgra2 strain
is one of the few type I knockouts that have reduced mouse
virulence [45]. While the reason for this reduced virulence is
unknown, it is known that GRA2 functions in the formation of the
tubulovesicular network in the Toxoplasma PVM [46], which
creates negative curvature in the PVM that might help to attract
Toxoplasma proteins secreted into the host cell back to the PVM
[47]. Indeed, it has been shown that the RHDgra2 strain has
reduced ROP18 localization to the tubulovesicular network in the
Toxoplasma PVM [47]. We therefore hypothesized that this GRA2-
dependent ROP18 and ROP5 localization and/or localization of
other proteins, would be important for IRG evasion. Indeed, the
RHDgra2 strain has significantly increased IRG coating to 36%
(P,0.001) and increased plaque loss on IFNc-stimulated MEFs to
24% (P= 0.08) (Figure 6B). Therefore, a protein required for the
formation of the PVM structure also affects IRG accumulation.
Strain differences in survival in IFNc-stimulated human
foreskin fibroblasts
We wondered if there are strain differences in the survival of
Toxoplasma in IFNc-stimulated human cells since strain differences
in virulence have been primarily studied in mice, and human cells
lack the multitude of IRGs present in murine cells. We measured
the percentage plaque loss of different types I, II and III strains as
well as of non-canonical strains in human foreskin fibroblasts
(HFFs) pre-stimulated for 24 hours with IFNc (Figure 7A). In
general, the percentage plaque loss in IFNc-stimulated HFFs is
higher than in IFNc-stimulated MEFs. The type I strains RH and
GT1 have plaque losses of 54% and 63%, respectively, while the
type II strains ME49 and Pru have plaque losses of 73% and 96%,
respectively and the type III strains CEP and VEG have plaque
losses of 90% and 67%, respectively. The non-canonical strains
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range in plaque loss from 47% (GUY-DOS) to 67% (CASTELLS).
Thus, strain susceptibility to IFNc-mediated killing in human cells
does not correlate with that of murine cells.
ROP18 and ROP5 have a minimal effect on IFNc-
mediated killing in human foreskin fibroblasts
As we have shown, ROP18 and ROP5 are responsible for most
of the strain differences in IFNc-susceptibility in murine cells, but
Toxoplasma IFNc-susceptibility in murine cells does not correlate
with IFNc-susceptibility in human cells. To test if ROP18 affects
IFNc-mediated killing in human cells, we first examined type III
strains transgenically expressing a virulent copy of ROP18. Neither
ROP18I nor ROP18II expression in type III decreases the
percentage plaque loss compared to the parental strain
(Figure 7B), suggesting that ROP18 is not responsible for strain
differences in IFNc-mediated killing in human cells. To see if
ROP5 affects survival in IFNc-activated human cells, we
compared the percent plaque loss in IFNc-stimulated HFFs
between S22 and S22 + LC37 and between Pru and Pru + LC37.
The plaque loss decreases from 87% for S22 to 76% for S22 +
LC37 (P= 0.03) and from 96% in Pru to 88% for Pru + LC37
(P= 0.01) (Figure 7C). Although the differences in plaque loss due
Figure 5. ROP5 interacts with Irga6, but not ROP18, and inhibits Irg6 oligomerization. (A) ROP5 and HA were immunoprecipitated from
IFNc-stimulated or unstimulated MEFs infected with CEP or CEP + ROP18II-HA and inputs and immunoprecipitates were Western blotted for ROP5
and HA. (B) Kinase activity of ROP18-HA immunoprecipitated from IFNc-stimulated or unstimulated MEFs infected with S22, S22 + ROP18II-HA or S22
+ LC37 + ROP18II-HA parasite strains. Half of the immunoprecipitated protein was Western blotted with anti-HA and the relative amount of ROP18-HA
from each strain was quantified using the ImageQuant (GE Healthcare Life Sciences) software. The remaining immunoprecipitated proteins were
incubated with 32P-c-ATP and a model peptide substrate (Lim, D., submitted) and spotted in quadruplicate onto phospho-cellulose paper where the
32P-c-ATP incorporation was quantified by phosphorimage analysis. The kinase activity is expressed as fold change over the S22 strain and
normalized to the relative amounts of ROP18-HA that was immunoprecipitated. This experiment was performed twice and the graph represents the
mean from those experiments. (C) Unique peptides (yellow) and percent sequence coverage of Irga6 recovered from mass spectrometry of proteins
co-immunoprecipitated with ROP5-CIII-HA. Briefly, HA-immunoprecipitated proteins from IFNc-stimulated or unstimulated MEFs infected with Pru,
Pru + ROP5-AIII-HA, Pru + ROP5-CIII-HA or RH + GRA15II-HA and lysed in the presence or absence of 0.5 mM GTPcS were separated by SDS-PAGE and
analyzed by MS/MS. Irga6 peptides were recovered only in ROP5-CIII-HA samples lysed in the presence of GTPcS. (D) Oligomerization of 20 mM Irga6
with10 mM GTP at 37uC in the presence of MBP-tagged ROP5-C or MBP shown as predicted mean hydrodynamic radius of the particle population
determined by dynamic light scattering.
doi:10.1371/journal.ppat.1002784.g005
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Figure 6. GRA2, but not ROP16 or GRA15, affects IRG evasion. WT MEFs stimulated for 24 hours with IFNc and infected with the indicated
strains for 1 hour and fixed for immunofluorescence or allowed to form plaques for 4–7 days. (A,B) Quantification of Irgb6 localization on the parasite
containing vacuole and percent plaque loss on stimulated MEFs compared to unstimulated MEFs infected with the indicated strains. Mean + SEM,
n.4 experiments. ***p,0.001, Student’s t-test.
doi:10.1371/journal.ppat.1002784.g006
Figure 7. Strain differences in survival in IFNc-stimulated human cells. Monolayers of HFFs, either previously stimulated for 24 hours with
IFNc or left untreated, were infected with 100–300 parasites. The number of plaques that form after 4–7 days of growth was determined. (A) Percent
plaque loss of type I strains RH and GT1, type II strains ME49 and Pru, type III strains CEP and VEG, as well as the non-canonical strains CASTELLS, GUY-
MAT, GUY-KOE, RUB, GUY-DOS and VAND. Mean + Std. dev., n$3 experiments. (B) Percent plaque loss for type III, type III + ROP18I and type III +
ROP18II. Mean + Std. dev., n$5 experiments. (C) Percent plaque loss of S22, S22 + LC37, Pru and Pru + LC37. Mean + Std. dev, n$4 experiments, *
p,0.05, Student’s t-test.
doi:10.1371/journal.ppat.1002784.g007
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to expression of ROP5 are significant, the differences are minimal
(610%). Thus, virulent alleles of ROP18 and ROP5 do not largely
affect parasite survival in IFNc-stimulated human cells.
Discussion
We report that the precise allelic combination of the Toxoplasma
polymorphic ROP18 and ROP5 genes determines Toxoplasma strain
differences in susceptibility to killing by IFNc-stimulated MEFs,
even for non-canonical strains. We also show that ROP18 and
ROP5 function by inhibiting the accumulation of and subsequent
killing by the IRGs. Toxoplasma strains also differ in their
susceptibility to killing by IFNc-stimulated HFFs, but this is not
determined by ROP18 or ROP5.
Previous studies on the role of ROP18 in mediating strain
differences in IRG accumulation on the PVM have produced
inconsistent results. Initial studies of in vivo primed macrophages
infected with the type III strain CTG expressing ROP18I and
L929 cells expressing ROP18I infected with the type II strain
ME49 showed minimal effects of ROP18 on Irgb6 and Irga6
coating [19,28]. More recently, ROP18I was shown to phosphor-
ylate a conserved threonine in the switch 1 loop of the GTPase
domain of Irga6 and Irgb6 leading to their subsequent inactivation
[30,31]. Here, we report that both ROP18I and ROP18II can
prevent the accumulation of IRGs on the PVM but only when
expressed in a genetic background that contains the virulent ROP5
locus. The lack of virulent ROP5 in type II strains therefore likely
explains why L929 expression of ROP18I did not affect IRG
accumulation on type II vacuoles in those cells [19].
Previously it was shown that the avirulent strain S22 transgenic
for the cosmid LC37, containing ROP5, had slightly fewer Irgb6
coated vacuoles (,72%) than wild type S22 (87%) in IFNc-
stimulated MEFs, but growth inhibition as measured by uracil
uptake was not affected [19]. In contrast, we see a significant
decrease in the percentage of vacuoles coated with Irgb6 and
increased parasite survival when comparing S22 + LC37 with S22.
This could be due to the concentration of IFNc, the exact assay
used or the genotype of the host cells used, as the IRGs are
divergent between mouse strains. We find that LC37 also reduces
Irgb6 coating and promotes parasite survival in Pru and BOF, and
that ROP5-C can explain most of the reduction in IRG coating in
vitro. However, Pru + LC37 was significantly more virulent in mice
than Pru + ROP5-CIII suggesting the other ROP5 genes may have
additional roles besides IRG evasion, in mouse virulence.
Currently, all Toxoplasma genes that determine strain differences
in virulence were identified using pairwise crosses between types I,
II and III. Because types I and III are progeny from a cross(es)
between type II and a strain named alpha (similar to type VI) and
beta (similar to type IX), respectively, these three strains are closely
related to each other [48]. In recent years it has become
appreciated that in South America, many other highly divergent
strains exist, and types I, II and III are rarely isolated. To date, no
studies have been done to determine the virulence determinants of
these strains. Here we report that for these strains the allelic
combination and/or expression level of ROP18 and ROP5 also
determine how well these strains evade the accumulation of the
IRGs and their virulence in mice. Surprisingly, even though the
North American/European and South American strains diverged
an estimated one million years ago [41], they all use the same two
genes to evade the murine IFNc response. This suggests that
evasion of host IRGs is crucial for Toxoplasma. However, most
strains do not completely evade the IRGs as this would be an
unsuccessful strategy to ensure transmission in mice as the host
would be killed before infectious cysts are formed. This could
mean that ROP18/ROP5 allelic combinations of highly virulent
strains might have evolved to evade the IRGs of species that are
more resistant to Toxoplasma, for example rats [49], and that mice
are just an accidental host or it could be an artifact of the mouse
lab strains commonly used. Strains such as type II, type III, BOF
(VI), P89 (IX) and CASTELLS (IV) that either lack (type II) or do
not express (BOF) virulent ROP5 alleles or do not express ROP18
(type III, P89 and CASTELLS) and are therefore less virulent in
mice seem better adapted to cause chronic infections in mice.
Indeed, the large majority of Toxoplasma isolates in North America
and Europe belong to type II [2].
ROP5 reduces IRG coating of the Toxoplasma PVM indepen-
dently of ROP18 despite a lack of kinase activity [42]. Many
pseudokinases have been shown to act as scaffolds or regulators of
active kinases [44]. We find that ROP5 is not necessary for
ROP18 kinase activity in vitro nor did we find evidence for any
direct interactions between ROP5 and ROP18 (Figure 5A). We
find instead that ROP5 directly interacts with and inhibits the
oligomerization of Irga6 (Figure 5C and D). Expression levels of
ROP5 seem to correlate with the intra-haplotype differences in
IRG coating between CEP and VEG, supporting a non-
enzymatic, dose-dependent inhibition of the IRGs by ROP5.
Importantly, both the IRGs and the ROP5 locus have expanded,
perhaps due to an evolutionary arms race whereby new host IRG
genes required new ROP5 genes so Toxoplasma could continue to
evade IFNc-mediated killing. Although ROP5 can inhibit IRG
oligomerization, we see an interactive effect with ROP18 on IRG-
coating and virulence. Perhaps the reduced oligomerization of
IRGs in the presence of virulent ROP5 alleles is reversible, but this
de-oligomerization might provide access for ROP18 to bind and
phosphorylate the IRGs on the threonines in their switch I loop, to
prevent re-activation. If this model is correct than the interaction
of ROP18 with the IRGs [30,31] should only occur in the
presence of virulent ROP5 alleles.
To defend itself against the IRGs Toxoplasma must have evolved
a mechanism to ensure appropriate trafficking of ROP18 and
ROP5 to the PVM upon their secretion into the host cytoplasm.
The N-terminal amphipathic helices (RAH domains) of both
proteins are required for efficient localization to the PVM, and it
was speculated that their specificity for the PVM versus other
membranes might be because of a preference for negative
curvature [47]. Indeed, we found that RHDgra2 parasites that
have a disrupted tubulovesicular network [46], which provides
much of the negative curvature of the PVM, have increased IRG
accumulation. This indicates that the attraction of ROP5, ROP18
and possibly other secreted proteins to the PVM, which is
attenuated in RHDgra2 [47], outweighs the possible attraction the
IRGs may have for the negative curvature of the PVM [50]. It is
likely that the increased IRG accumulation on the PVM of
RHDgra2 accounts for its decrease in virulence [45].
Because all Toxoplasma strains seem to rely on ROP5 and
ROP18 for evasion of the murine IFNc response, these proteins
could be attractive drug targets if they are also involved in evasion
of the human IFNc response. However, we find that although
there are significant strain differences in susceptibility to IFNc-
mediated killing by HFFs, ROP5 and ROP18 do not markedly
affect survival in those cells. This might not be surprising because
humans do not possess the large variety of IRGs of murine cells (23
members) but only a single member (IRGM) that is not regulated
by IFNc [22]. The effector mechanisms induced by IFNc in
human cells that are effective against Toxoplasma include trypto-
phan degradation [25], iron depletion [51], P2X7-mediated death
of the host cell [52] and activation of the NALP1 inflammasome
[27]. While the IRGs do not mediate vacuolar destruction in
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human cells, we wondered if another group of dynamin-related
large GTPase, the GBPs, could be involved in IFNc-mediated
killing by HFFs, but we failed to see GBP1 at the PVM in HFFs
(data not shown).
The Toxoplasma strains that were most resistant to IFNc-
mediated killing by HFFs have also been shown to be able to cause
severe disease even in immunocompetent humans. In future
studies, strain differences in survival in IFNc-activated HFFs may
provide insight into that mechanism.
Materials and Methods
Reagents
A rat monoclonal antibody against HA (3F10, Roche, 1:500
dilution), a goat polyclonal antibody against mouse TGTP (A-20,
Santa Cruz Biotechnology, 1:100 dilution), a mouse monoclonal
antibody against Toxoplasma surface antigen (SAG)-1 (DG52) [53],
and a mouse polyclonal antibody against the N-terminus of ROP5
[54] were used in immunofluorescence assays or immunoprecip-
itations. Secondary antibodies for immunofluorescence were
coupled with Alexa Fluor 488 or Alexa Fluor 594 (Molecular
Probes). Secondary antibodies used in Western blotting were
conjugated to peroxidase (Kirkegaard & Perry Laboratories).
Mouse IFNc from Peprotech and human IFNc from AbD serotec
were dissolved in DMEM with 10% FBS.
Parasites and cells
Parasites were maintained in vitro by serial passage on
monolayers of human foreskin fibroblasts (HFFs) at 37uC in 5%
CO2. The following representatives for each haplotype were used:
RH and GT1 for type I, ME49 and Pru for type II, CEP and VEG
for type III, MAS and CASTELLS for type IV, GUY-KOE and
GUY-MAT for type V, GPHT and BOF for type VI, CAST for
type VII, TgCatBr5 for type VIII, P89 for type IX, GUY-DOS
and VAND for type X and COUGAR for type XI. A Pru strain
engineered to express firefly luciferase and GFP (PruDHXGPRT
A7) [55], a CEP and RH strain engineered to express clickbeetle
luciferase and GFP (CEPDHXGPRT C22 and RH 1-1) [56], CEP
+ ROP18II, Pru + ROP16I [7], RHDgra2 [45], RHDrop16 [57],
RH + GRA15II and CEP + GRA15II [36] have been described
previously. HFFs were grown as described previously [36]. WT
C57BL6/J MEFs were a gift from A. Sinai (University of
Kentucky College of Medicine, Lexington, KY), Atg7+/2 and
Atg72/2 MEFs [58] from Masaaki Komatsu (The Tokyo
Metropolitan Institute Medical Science) and all MEFs were grown
in HFF media supplemented with 10 mM Hepes. All parasite
strains and cell lines were routinely checked for Mycoplasma
contamination and it was never detected.
Immunofluorescence assays
Monolayers of MEF cells grown on coverslips and incubated for
24 hours with or without 1000 U/ml IFNc. Parasites were
allowed to invade for 20 minutes, non-invading parasites were
then washed away with PBS 3 times, and the infection proceeded
for 1 hour. The cells were then fixed with 3% (v/v) formaldehyde
in PBS for 20 minutes at room temperature, permeabilized with
0.2% saponin and blocked in PBS with 3% (w/v) BSA and 5% (v/
v) FBS. Percent Irgb6 coating was determined in a blind fashion by
finding intracellular parasites and then scoring Irgb6 coating as
positive or negative.
Characterization of ROP5 sequences
The coding sequence for ROP5 from types I (GT1), II (ME49),
and III (VEG) was predicted from ToxoDB genomic sequence
using ORF Finder (NCBI). ROP5 genomic DNA from additional
strains was amplified by PCR with isoform specific primers
confirmed by sequence chromatograms. ROP5 was amplified with
the following primers forward 59CGATTCACGCTTTC-
CATGT93, reverse 59TCCTTCAGCGGAAAACAGAT93 for
ROP5-A, forward 59CATTTCATGCCTTCCCAGTT93, reverse
59GCGCTCGAGTACTTGTCCTG93 for ROP5-B/C, forward
59GTCCCTGGAAAACTGTTTCG93, reverse 59GTGAACA-
GAGAGCGTCCAA93 for ROP5-D, forward 59ATTCTGCA-
ATGCCCAAAAGA93, reverse 59TTCATGTTGGATACGG-
CAAC93 for ROP5-E and 59AAAAGGCGCGGCGAGC-
TAGCGTC93 as an alternate forward primer for ROP5-A for
MAS and CASTELLS.
The ROP5-B/C PCR products produced mixed sequence and
therefore the PCR product was cloned and multiple clones were
sequenced.
The following primers were used to sequence ROP5-A and
ROP5-B 59ATAGGTAACCGGGACGCTTG93, 59CCACTT-
CGGAAGAGACTTGC93, 59GGACAGACGCAGGCTTTTA-
C93
The following primers were used to sequence ROP5-D and
ROP5-E 59TGAGCTGAAAACCGACTTCAC93, 59GGTGA-
CTGGAACACTCGACA93, 59TTTTCCGGACCTTGTCTT-
TG93, 59TTCGGGAGAGACTTGCTCAG93, 59GCTGTGA-
CAGTTCCGACTCA93
Sequences were aligned using ClustalX and Neighbor-Joining
phylogenetic trees were made with Molecular Evolutionary
Genetic Analysis (MEGA) software version 4.1 with 1000
bootstraps and default settings [59]. The Non-synonymous
Analysis Program (SNAP) was used to calculate the proportion
of synonymous and non-synonymous changes in coding regions
[60].
Generation of transgenic parasites
The coding region and putative promoter (766 bp upstream of
the start codon for ROP5-A and 681 bp upstream for ROP5-B) of
ROP5-A and ROP5-B was amplified from type III Toxoplasma
genomic DNA by PCR (A forward, 59-CCACGCATTCTTC-
CACTCAGTACCG-39; B forward, 59-CCACAATGGCTAC-
CAGGTCCTGCG-39; A/B reverse, 59-CTACGCGTAGTCCGG-
GACGTCGTACGGGTAAGCGACTGAGGGCGC-39). The
coding region of ROP18, along with putative promoter (742 bp
upstream of the ATG start codon), from type I Toxoplasma genomic
DNA was amplified by PCR. (Forward 59-CACCAGATTC-
GAAACGCGGAAGTA-39; Reverse 59-TTACGCGTAGTCC-
GGGACGTCGTACGGGTATTCTGTGTGGAGATGTTCC-
TGCTGTTC -39). These primers amplified these genes specifi-
cally as confirmed by sequencing and the sequence matched the
previously published data [30–34]. Sequence coding for an HA tag
was included in the reverse primer (denoted with italics) to C-
terminally tag the protein. ROP5-AIIIHA, ROP5-CIIIHA and
ROP18I were then cloned into pENTR/D-TOPO (Invitrogen),
and then cloned into pTKO-att (described in [58]) by LR
recombination (Invitrogen). The pTKO-att-ROP5IIIHA vectors
were then linearized by digestion with HindIII (NEB), which does
not cut inside either gene. Linearized vector was transfected into
PruDHXGPRT parasites by electroporation as described previ-
ously [58]. The pTKO-att-ROP18 vector was linearized by
digestion with NdeI (NEB) and transfected into CEPDHXGPRT
C22 parasites by electroporation. Stable integrants were selected
in media with 25 mg/ml mycophenolic acid (Axxora) and 25 mg/
ml xanthine (Alfa Aesar) and cloned by limiting dilution. To
express ROP18II in the S22 and S22 LC37 parasite strains, 35 mg
of pTKO-att-ROP18IIHA [1] was linearized by HindIII (NEB)
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and 1 mg of pTUB-CAT were co-transfected by electroporation.
Stable integrants were selected by passage of 106 parasites every 2
days in 2 mM chloramphenicol. Expression of ROP18 and
ROP5III was confirmed by IF and Western blot for HA staining
(Figure 6A–D). The LC37 cosmid from the pSC/Ble library (gift of
M.J. Gubbels, Boston College, Boston, MA) was expressed in
PruDHXGPRT A7 and BOF by transfecting 50 mg cosmid and
selecting twice extracellularly for 1.5 hours with 5 mg/ml phleo-
mycin. Integration was confirmed by PCR with the Type I ROP5
specific forward primer (59-TTTTCCGCAGGCCGTGGC-39)
and ROP5A/B reverse for Pru and amplification of ROP5-A for
BOF.
Plaque assays
For the plaque assays, 100–300 parasites per well were added to
monolayers of MEFs seeded the day before or HFFs seeded two
days before and either previously stimulated with 1000 U/ml
mouse IFNc, 100 U/ml human IFNc or left unstimulated for
24 hours before infection in a 24 well plate in either MEF media
or DMEM with 1% FBS for HFFs. Infections were then incubated
for 4–7 days at 37uC and the number of plaques was counted using
a microscope.
In vivo imaging analysis
CD-1 (Charles River Laboratories) mice were intraperitoneally
(i.p.) infected with 500 or 5000 syringe-lysed tachyzoites in 300 ml
PBS using a 28 gauge needle. On days 3, 6 and 12 post infection,
parasite burden and dissemination was measured by biolumines-
cence emission imaging. Mice were injected i.p. with 3 mg firefly
D-luciferin (Gold Biotechnology) dissolved in PBS, anesthetized
with isofluorane, and imaged with an IVIS Spectrum-biolumines-
cent and fluorescent imaging system (Xenogen Corporation).
Images were processed and analyzed with Living Image software.
The MIT Committee on Animal Care approved all protocols. All
mice were maintained in specific pathogen-free conditions, in
accordance with institutional and federal regulations.
High-throughput genomic and RNA sequencing
For genomic sequencing, DNA was isolated from freshly lysed
Toxoplasma parasites using a Trizol-based extraction (Invitrogen).
This DNA was subsequently prepared for high-throughput
sequencing according to the Illumina single-end genomic DNA
kit protocol (COUGAR, CASTELLS and MAS) and 36
nucleotides of each library was sequenced on an Illumina GAII
and processed using the standard Illumina pipeline. Paired-end
sequencing Illumina libraries were constructed for the genomic
DNA of P89, GUY-KOE, TgCatBr5, BOF using the Nextera
Illumina compatible DNA sample prep kit (Epicenter) and
amplified with the modified PCR protocols described previously
[61]. Sequence reads were aligned to the Toxoplasma and human
genomes using the Maq software package [62]. Reference
Toxoplasma genomes from a type II (Me49), a type I (GT1) and a
type III (VEG) strain were obtained from http://toxodb.org
(release 6.3). For RNA sequencing, murine bone-marrow derived
macrophages (BMDM) were seeded in 6 well plates at 70%
confluency and infected with different strains of Toxoplasma at three
multiplicity of infections (MOIs): 15, 10 and 7.5. After 24 hours
total RNA was extracted from all infected cells using the Qiagen
RNeasy Plus kit. Integrity, size and concentration of RNA was
then checked using the Agilent 2100 Bioanalyzer. The RNA was
processed for high-throughput sequencing according to standard
Illumina protocols. Briefly, after mRNA pull down from total
RNA using Dynabeads mRNA Purification Kit (Invitrogen),
mRNA was fragmented into 200-400 base pair-long fragments
and reverse transcribed to into cDNA, before Illumina sequencing
adapters were added to each end. Libraries were barcoded and
subject to paired end sequencing on the Illumina HiSeq2000
(40+40 nucleotides) and processed using the standard Illumina
pipeline. All libraries were spiked with trace amounts of the phiX
bacteriophage for quality control purposes. After sequencing, the
samples were de-barcoded to separate reads from the multiplexed
samples using a custom Perl script. Reads were assembled into full
sequences by mapping to exons and across exon junctions using
the organism’s genomes as a template. Maq was used to estimate
Toxoplasma transcript abundance for ROP5 and ROP18 based on
our sequenced alleles. A more detailed analysis of the genome and
RNA-seq data will be described elsewhere.
Immunoprecipitations, Western blotting and kinase
assays
Immunoprecipitations were each performed with 5 mg of rat
anti-HA (3F10, Roche) or mouse anti-ROP5 [54] conjugated to
25 ml of protein G dynabead slurry (Life Technologies). The HA
antibodies were crosslinked at room temperature with 5 mM
Bis(Sulfosuccinimidyl) suberate (BS3) (Pierce) prepared in conju-
gation buffer (20 mM sodium phosophate, 150 mM sodium
chloride, pH 7.5) for 30 minutes and quenched by adding
50 mM Tris-Cl, pH 7.5 for 15 minutes and finally washed with
conjugation buffer. For each immunoprecipitation (IP) condition,
4.26106 MEFs were infected at an MOI of ,5–10, with the strain
and condition indicated. After 1 hour, uninvaded parasites were
washed away with PBS and the infected cells were treated with
0.25% trypsin for 5 minutes at 37uC. The cells were quenched and
harvested with growth media and subsequently washed with PBS +
1 mM PMSF and lysed for 15 minutes at 4uC with light agitation
in 1 ml of IP lysis buffer [50 mM HEPES-KOH (pH 7.5),
300 mM NaCl, 10 mM b-glycerophosphate, 1 mM NaF,
0.1 mM NaVO4, 1 mM PMSF, 1% NP-40, and protease inhibitor
cocktail (Roche)]. The lysate was then centrifuged at 16,000 g for
30 minutes at 4uC and the supernatant was collected. For ROP18
binding assays, 1 mg of ROP18 recombinant kinase domain
[residues 187–554, fused to a series of N-terminal fusion tags
consisting of: (His6)-(glutathione S-transferase)-(maltose binding
protein)-(Streptococcus protein B1 domain)-(TEV cleavage site),
(Lim, D et al., submitted)] were incubated for 30 minutes before
adding conjugated and crosslinked antibody beads described
above and agitating them for 3 hours at 4uC. The beads were
washed 3 times with IP wash buffer [10 mM HEPES-KOH
(pH 7.5), 150 mM NaCl, 20 mM b-glycerophosphate, and 0.5%
NP-40], washed 36with HEPES-buffered saline (HBS) and boiled
in sample buffer. The samples were western blotted with anti-GST
HRP conjugate (GE Healthcare Life Sciences) and anti-HA (3F10,
Roche) antibodies.
Immunoprecipitations for kinase assays were performed as
above but with several changes. The cleared lysates were
incubated with 10 mg of rat anti-HA (3F10, Roche) per IP
reaction and incubated for 90 minutes, washed 5 times with the IP
lysis buffer and 3 times with IP wash buffers and HBS (all buffers
contained 300 mM NaCl). Half of the beads were boiled in sample
buffer for western blotting with anti-HA and the other half used
for the kinase assay. Kinase assays using a ROP18 model peptide
substrate (NH3-KKKKKWISEHTRYFF-CONH2) (Lim, D. et
al., submitted) were conducted at room temperature with a
reaction buffer consisting of 50 mM HEPES pH 7.5, 300 mM
NaCl, 10 mM DTT, 10 mM MgSO4 and 60 mM cold ATP. Each
reaction contained 0.5 mM of peptide substrate and 2 to 10 mCi of
32P-c-ATP. Reactions were stopped after 30 minutes by spotting
on Whatman P81 phospho-cellulose paper, which were then dried
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and washed with 0.425% phosphoric acid until no significant
radioactivity remained in the washes. Radioactivity captured on
P81 filters was then quantified by phosphorimage analysis with
ImageQuant 5.2 software (Molecular Dynamics). The radioactiv-
ity detected was normalized to the amount of protein immuno-
precipitated as determined by the above Western blot.
Mass spectrometry
Immunoprecipitations were performed as above with a mono-
layer of confluent MEFs in a T175 lysed in the presence or
absence of 0.5 mM GTPcS (Sigma) and precipitated using 30 mg
of HA antibody. The washed beads were boiled in sample buffer
and samples were subjected to SDS–PAGE and colloidal
coomassie (Invitrogen) staining. For mass spectrometry analysis,
proteins were excised from each lane of a coomassie-stained SDS-
PAGE gel encompassing the entire molecular weight range.
Trypsin digested extracts were analyzed by reversed phase HPLC
and a ThermoFisher LTQ linear ion trap mass spectrometer.
Peptides were identified from the MS data using SEQUEST
algorithms44 that searched a species-specific database generated
from NCBI’s non-redundant (nr.fasta) database.
Dynamic light scattering
Recombinant Irga6 [residues 1–413, fused to a series of N-
terminal fusion tags consisting of: (His6)-(glutathione S-transfer-
ase)-(maltose binding protein)-(Streptococcus protein B1 domain)-
(TEV cleavage site), (Lim et al, submitted)] oligomerization was
monitored in 50 mM Tris/5 mM MgCl2/2 mM DTT by
dynamic light scattering (DLS). Oligomerization was initiated by
the addition of 10 mM GTP (Sigma) to 20 mM Irga6 in the
presence or absence of 40 mM recombinant (His6)-MBP-tagged
ROP5-CIII or (His6)-MBP. The reaction was mixed by pipetting
and immediately transferred to a quartz cuvette and equilibrated
to 37uC. DLS was performed using a DynaPro NanoStar Light
Scatterer (Wyatt Technologies) with an acquisition time of 10 sec
over 35 minutes and analyzed using the DYNAMICS software
version 7.1.4. The mean hydrodynamic radius of the population
was estimated using the standard curve of molecular weight for
globular proteins and is not equal to the actual size of the
oligomer.
Ethics statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of Laboratory
Animals of the National Institutes of Health. The MIT Committee
on Animal Care (assurance number A-3125-01) approved all
protocols. All mice were maintained in specific pathogen-free
conditions, and all efforts were made to minimize suffering.
Accession numbers
Sequences can be accessed in GenBank: ROP5-BL sequences
JQ743705–JQ743719, ROP5-AL JQ743720–JQ743735,
ROP5A–C sequences JQ743736–JQ743783.
Supporting Information
Figure S1 IFNc-induced plaque loss is reduced when the
IRGs are mis-regulated. Monolayers of Atg7+/2 and
Atg72/2 MEFs were stimulated for 24 hours with IFNc and
infected with type II (Pru) for 1 hour or allowed to form plaques
for 7 days. Immunofluorescence of Irgb6 PV coating and percent
plaque loss on stimulated compared to unstimulated MEFs. Mean
+ SEM, n= 3 experiments, *P,0.05, ***P,0.001, Student’s t-test.
(TIF)
Figure S2 Phylogenetic analysis of ROP18. Phylogenetic
analysis of coding nucleotide sequences by Neighbor Joining with
1000 bootstraps of ROP18 alleles [11].
(TIF)
Figure S3 Phylogenetic analysis and expression of
ROP5L-A and B. (A) ROP5L-A and B (B) phylogenetic analysis
of coding nucleotide sequences by Neighbor Joining and
cumulative mutations codon by codon by type (C and D
respectively). E) Expression by RNA-Seq analysis of 24 hour
infection with indicated strains in bone marrow-derived macro-
phages.
(TIF)
Figure S4 Amino acid alignments of sequenced ROP5
genes. Amino acid alignments of ROP5-A and B/C as well as
ROP5L-A and B for sequenced strains.
(PDF)
Figure S5 ROP5 does not directly interact with ROP18
and is not necessary for ROP18 kinase activity. (A) Wild-
type (wt) or mutant R223E recombinant proteins comprising the
kinase domain (KD) of ROP18I fused to MBP-GST were added to
lysates prepared from IFNc-stimulated and unstimulated MEFs
infected with type II or type II + ROP5CIII-HA parasites and
incubated for 30 minutes before immunoprecipitating the reac-
tions with anti-HA. Both the immunoprecipitates (lanes 1–6) and
pre-IP lysates (lanes 7–12) were Western blotted with anti-GST
and anti-HA. (B) Kinase activity of ROP18-HA immunoprecip-
itated from IFNc-stimulated or unstimulated MEFs infected with
S22, S22 + ROP18II-HA or S22 + LC37 + ROP18II-HA parasite
strains. Half of the immunoprecipitated protein was Western
blotted with anti-HA (top). The remaining immunoprecipitated
proteins were incubated with 32P-c-ATP and a model peptide
substrate (Lim, D., submitted) and spotted in quadruplicate onto
phospho-cellulose paper where the 32P-c-ATP incorporation was
quantified by phosphorimage analysis (bottom). This experiment
was performed twice and the graph represents the mean from
those experiments.
(TIF)
Figure S6 Expression and localization of transgenic
ROP18 and ROP5. (A) Immunofluorescence of HA (red) in
S22 + ROP18II-HA and S22 + LC37 + ROP18II-HA parasites as
well as DIC and merged images. (B) Western blot for HA (top) and
SAG1 (bottom) comparing expression of S22 + ROP18II-HA and
S22 + LC37 + ROP18II-HA strains used for mouse infections. (C)
Immunofluorescence of HA (red) in Pru + ROP5-AIII-HA and Pru
+ ROP5-CIII-HA parasites as well as DIC and merged images. (D)
Western blot for HA (top) and SAG1 (bottom) comparing
expression of Pru + ROP5-AIII-HA and Pru + ROP5-CIII-HA
strains used for mouse infections.
(TIF)
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